1. Home
  2. ATYR vs SY Comparison

ATYR vs SY Comparison

Compare ATYR & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • SY
  • Stock Information
  • Founded
  • ATYR 2005
  • SY 2013
  • Country
  • ATYR United States
  • SY China
  • Employees
  • ATYR N/A
  • SY N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • SY EDP Services
  • Sector
  • ATYR Health Care
  • SY Technology
  • Exchange
  • ATYR Nasdaq
  • SY Nasdaq
  • Market Cap
  • ATYR 535.0M
  • SY 482.1M
  • IPO Year
  • ATYR 2015
  • SY 2019
  • Fundamental
  • Price
  • ATYR $5.63
  • SY $3.70
  • Analyst Decision
  • ATYR Strong Buy
  • SY Strong Buy
  • Analyst Count
  • ATYR 5
  • SY 1
  • Target Price
  • ATYR $23.25
  • SY $5.50
  • AVG Volume (30 Days)
  • ATYR 4.3M
  • SY 1.9M
  • Earning Date
  • ATYR 11-06-2025
  • SY 08-15-2025
  • Dividend Yield
  • ATYR N/A
  • SY 0.72%
  • EPS Growth
  • ATYR N/A
  • SY N/A
  • EPS
  • ATYR N/A
  • SY N/A
  • Revenue
  • ATYR N/A
  • SY $197,807,588.00
  • Revenue This Year
  • ATYR $478.72
  • SY $8.61
  • Revenue Next Year
  • ATYR $1,899.26
  • SY $54.55
  • P/E Ratio
  • ATYR N/A
  • SY N/A
  • Revenue Growth
  • ATYR N/A
  • SY N/A
  • 52 Week Low
  • ATYR $1.67
  • SY $0.66
  • 52 Week High
  • ATYR $7.29
  • SY $6.28
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 58.33
  • SY 44.61
  • Support Level
  • ATYR $5.08
  • SY $3.66
  • Resistance Level
  • ATYR $5.77
  • SY $4.16
  • Average True Range (ATR)
  • ATYR 0.42
  • SY 0.31
  • MACD
  • ATYR 0.02
  • SY -0.02
  • Stochastic Oscillator
  • ATYR 66.67
  • SY 27.79

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.

Share on Social Networks: